ID   CO4B_HUMAN              Reviewed;        1744 AA.
AC   P0C0L5; A2BHY4; P01028; P78445; Q13160; Q13906; Q14033; Q14835; Q6U2E9;
AC   Q6U2G1; Q6U2I5; Q6U2L1; Q6U2L7; Q6U2L9; Q6U2M5; Q6VCV8; Q96SA7; Q9NPK5;
AC   Q9UIP5;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2013, sequence version 2.
DT   03-AUG-2022, entry version 158.
DE   RecName: Full=Complement C4-B;
DE   AltName: Full=Basic complement C4;
DE   AltName: Full=C3 and PZP-like alpha-2-macroglobulin domain-containing protein 3;
DE   Contains:
DE     RecName: Full=Complement C4 beta chain;
DE   Contains:
DE     RecName: Full=Complement C4-B alpha chain;
DE   Contains:
DE     RecName: Full=C4a anaphylatoxin;
DE   Contains:
DE     RecName: Full=C4b-B;
DE   Contains:
DE     RecName: Full=C4d-B;
DE   Contains:
DE     RecName: Full=Complement C4 gamma chain;
DE   Flags: Precursor;
GN   Name=C4B; Synonyms=CO4, CPAMD3;
GN   and
GN   Name=C4B_2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-1317.
RC   TISSUE=Blood;
RX   PubMed=8575831; DOI=10.1007/bf00587313;
RA   Ulgiati D., Townend D.C., Christiansen F.T., Dawkins R.L., Abraham L.J.;
RT   "Complete sequence of the complement C4 gene from the HLA-A1, B8, C4AQ0,
RT   C4B1, DR3 haplotype.";
RL   Immunogenetics 43:250-252(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TYR-347 AND ALA-907.
RA   Rowen L., Dankers C., Baskin D., Faust J., Loretz C., Ahearn M.E.,
RA   Banta A., Swartzell S., Smith T.M., Spies T., Hood L.;
RT   "Sequence determination of 300 kilobases of the human class III MHC
RT   locus.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ALA-907 AND ASP-1073.
RA   Sayer D., Puschendorf M., Wetherall J.;
RT   "Molecular genetics of complement C4: implications for MHC evolution and
RT   disease susceptibility gene mapping.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS TYR-347 AND
RP   ALA-907.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [5]
RP   PROTEIN SEQUENCE OF 680-756.
RX   PubMed=6167582; DOI=10.1016/s0021-9258(19)68898-8;
RA   Moon K.E., Gorski J.P., Hugli T.E.;
RT   "Complete primary structure of human C4a anaphylatoxin.";
RL   J. Biol. Chem. 256:8685-8692(1981).
RN   [6]
RP   PROTEIN SEQUENCE OF 757-771 AND 980-990.
RX   PubMed=1699796; DOI=10.1016/0014-5793(90)80389-z;
RA   Hessing M., van 't Veer C., Hackeng T.M., Bouma B.N., Iwanaga S.;
RT   "Importance of the alpha 3-fragment of complement C4 for the binding with
RT   C4b-binding protein.";
RL   FEBS Lett. 271:131-136(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 956-1336, AND VARIANT ASP-1073.
RC   TISSUE=Liver;
RX   PubMed=6546707; DOI=10.1016/0092-8674(84)90040-0;
RA   Belt K.T., Carroll M.C., Porter R.R.;
RT   "The structural basis of the multiple forms of human complement component
RT   C4.";
RL   Cell 36:907-914(1984).
RN   [8]
RP   PROTEIN SEQUENCE OF 957-1044.
RX   PubMed=6978711; DOI=10.1042/bj1990359;
RA   Campbell R.D., Gagnon J., Porter R.R.;
RT   "Amino acid sequence around the thiol and reactive acyl groups of human
RT   complement component C4.";
RL   Biochem. J. 199:359-370(1981).
RN   [9]
RP   PROTEIN SEQUENCE OF 957-1336.
RX   PubMed=3696167; DOI=10.1016/0161-5890(87)90165-9;
RA   Chakravarti D.N., Campbell R.D., Porter R.R.;
RT   "The chemical structure of the C4d fragment of the human complement
RT   component C4.";
RL   Mol. Immunol. 24:1187-1197(1987).
RN   [10]
RP   PROTEIN SEQUENCE OF 990-1037.
RX   PubMed=6950384; DOI=10.1073/pnas.78.12.7388;
RA   Harrison R.A., Thomas M.L., Tack B.F.;
RT   "Sequence determination of the thiolester site of the fourth component of
RT   human complement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 78:7388-7392(1981).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1055-1225 (ALLOTYPE C4B12).
RX   PubMed=9759862;
RA   Martinez-Quiles N., Paz-Artal E., Moreno-Pelayo M.A., Longas J.,
RA   Ferre-Lopez S., Rosal M., Arnaiz-Villena A.;
RT   "C4d DNA sequences of two infrequent human allotypes (C4A13 and C4B12) and
RT   the presence of signal sequences enhancing recombination.";
RL   J. Immunol. 161:3438-3443(1998).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1055-1225, AND VARIANTS ASN-1176;
RP   VAL-1207 AND LEU-1210.
RX   PubMed=14989716; DOI=10.1111/j.0001-2815.2004.00147.x;
RA   Lopez-Goyanes A., Moreno M.A., Ferre S., Paz-Artal E.;
RT   "C4d DNA sequence of complement C4B93 and recombination mechanisms for its
RT   generation.";
RL   Tissue Antigens 63:260-262(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 1199-1304.
RX   PubMed=6832377; DOI=10.1016/0014-5793(83)80188-4;
RA   Chakravarti D.N., Campbell R.D., Gagnon J.;
RT   "Amino acid sequence of a polymorphic segment from fragment C4d of human
RT   complement component C4.";
RL   FEBS Lett. 154:387-390(1983).
RN   [14]
RP   PROTEIN SEQUENCE OF 1405-1431, AND SULFATION AT TYR-1417; TYR-1420 AND
RP   TYR-1422.
RX   PubMed=3944109; DOI=10.1016/s0021-9258(17)36009-x;
RA   Hortin G., Sims H., Strauss A.W.;
RT   "Identification of the site of sulfation of the fourth component of human
RT   complement.";
RL   J. Biol. Chem. 261:1786-1793(1986).
RN   [15]
RP   INVOLVEMENT IN C4BD AND SLE.
RX   PubMed=3265961;
RA   Wilson W.A., Perez M.C.;
RT   "Complete C4B deficiency in black Americans with systemic lupus
RT   erythematosus.";
RL   J. Rheumatol. 15:1855-1858(1988).
RN   [16]
RP   INTERACTION WITH CR1.
RX   PubMed=2972794; DOI=10.1084/jem.168.5.1699;
RA   Klickstein L.B., Bartow T.J., Miletic V., Rabson L.D., Smith J.A.,
RA   Fearon D.T.;
RT   "Identification of distinct C3b and C4b recognition sites in the human
RT   C3b/C4b receptor (CR1, CD35) by deletion mutagenesis.";
RL   J. Exp. Med. 168:1699-1717(1988).
RN   [17]
RP   FUNCTION, INVOLVEMENT OF HIS-1125 IN IMMUNOGLOBULIN-BINDING AND HEMOLYSIS,
RP   AND MUTAGENESIS OF LEU-1120; SER-1121; ILE-1124 AND HIS-1125.
RX   PubMed=2395880; DOI=10.1073/pnas.87.17.6868;
RA   Carroll M.C., Fathallah D.M., Bergamaschini L., Alicot E.M., Isenman D.E.;
RT   "Substitution of a single amino acid (aspartic acid for histidine) converts
RT   the functional activity of human complement C4B to C4A.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:6868-6872(1990).
RN   [18]
RP   INTERACTION WITH CR1.
RX   PubMed=8175757; DOI=10.1016/s0021-9258(17)36829-1;
RA   Krych M., Clemenza L., Howdeshell D., Hauhart R., Hourcade D.,
RA   Atkinson J.P.;
RT   "Analysis of the functional domains of complement receptor type 1 (C3b/C4b
RT   receptor; CD35) by substitution mutagenesis.";
RL   J. Biol. Chem. 269:13273-13278(1994).
RN   [19]
RP   FUNCTION.
RX   PubMed=8538770; DOI=10.1038/379177a0;
RA   Dodds A.W., Ren X.D., Willis A.C., Law S.K.;
RT   "The reaction mechanism of the internal thioester in the human complement
RT   component C4.";
RL   Nature 379:177-179(1996).
RN   [20]
RP   INVOLVEMENT IN SLE.
RX   PubMed=10092831;
RA   Lokki M.L., Circolo A., Ahokas P., Rupert K.L., Yu C.Y., Colten H.R.;
RT   "Deficiency of human complement protein C4 due to identical frameshift
RT   mutations in the C4A and C4B genes.";
RL   J. Immunol. 162:3687-3693(1999).
RN   [21]
RP   REVIEW, DESCRIPTION OF ALLOTYPES, AND TISSUE SPECIFICITY.
RX   PubMed=11367523; DOI=10.1016/s1567-5769(01)00019-4;
RA   Blanchong C.A., Chung E.K., Rupert K.L., Yang Y., Yang Z., Zhou B.,
RA   Moulds J.M., Yu C.Y.;
RT   "Genetic, structural and functional diversities of human complement
RT   components C4A and C4B and their mouse homologues, Slp and C4.";
RL   Int. Immunopharmacol. 1:365-392(2001).
RN   [22]
RP   GLYCOSYLATION AT ASN-226.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [23]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1391.
RC   TISSUE=Plasma;
RX   PubMed=14760718; DOI=10.1002/pmic.200300556;
RA   Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.;
RT   "Screening for N-glycosylated proteins by liquid chromatography mass
RT   spectrometry.";
RL   Proteomics 4:454-465(2004).
RN   [24]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1328.
RC   TISSUE=Saliva;
RX   PubMed=16740002; DOI=10.1021/pr050492k;
RA   Ramachandran P., Boontheung P., Xie Y., Sondej M., Wong D.T., Loo J.A.;
RT   "Identification of N-linked glycoproteins in human saliva by glycoprotein
RT   capture and mass spectrometry.";
RL   J. Proteome Res. 5:1493-1503(2006).
RN   [25]
RP   STRUCTURAL BASIS OF POLYMORPHISM.
RX   PubMed=2431902; DOI=10.1002/j.1460-2075.1986.tb04582.x;
RA   Yu C.Y., Belt K.T., Giles C.M., Campbell R.D., Porter R.R.;
RT   "Structural basis of the polymorphism of human complement components C4A
RT   and C4B: gene size, reactivity and antigenicity.";
RL   EMBO J. 5:2873-2881(1986).
RN   [26]
RP   INVOLVEMENT IN SLE.
RX   PubMed=17503323; DOI=10.1086/518257;
RA   Yang Y., Chung E.K., Wu Y.L., Savelli S.L., Nagaraja H.N., Zhou B.,
RA   Hebert M., Jones K.N., Shu Y., Kitzmiller K., Blanchong C.A., McBride K.L.,
RA   Higgins G.C., Rennebohm R.M., Rice R.R., Hackshaw K.V., Roubey R.A.,
RA   Grossman J.M., Tsao B.P., Birmingham D.J., Rovin B.H., Hebert L.A.,
RA   Yu C.Y.;
RT   "Gene copy-number variation and associated polymorphisms of complement
RT   component C4 in human systemic lupus erythematosus (SLE): low copy number
RT   is a risk factor for and high copy number is a protective factor against
RT   SLE susceptibility in European Americans.";
RL   Am. J. Hum. Genet. 80:1037-1054(2007).
RN   [27]
RP   POLYMORPHISM, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=26814963; DOI=10.1038/nature16549;
RG   Schizophrenia Working Group of the Psychiatric Genomics Consortium;
RA   Sekar A., Bialas A.R., de Rivera H., Davis A., Hammond T.R., Kamitaki N.,
RA   Tooley K., Presumey J., Baum M., Van Doren V., Genovese G., Rose S.A.,
RA   Handsaker R.E., Daly M.J., Carroll M.C., Stevens B., McCarroll S.A.;
RT   "Schizophrenia risk from complex variation of complement component 4.";
RL   Nature 530:177-183(2016).
CC   -!- FUNCTION: Non-enzymatic component of the C3 and C5 convertases and thus
CC       essential for the propagation of the classical complement pathway.
CC       Covalently binds to immunoglobulins and immune complexes and enhances
CC       the solubilization of immune aggregates and the clearance of IC through
CC       CR1 on erythrocytes. C4A isotype is responsible for effective binding
CC       to form amide bonds with immune aggregates or protein antigens, while
CC       C4B isotype catalyzes the transacylation of the thioester carbonyl
CC       group to form ester bonds with carbohydrate antigens.
CC   -!- FUNCTION: Derived from proteolytic degradation of complement C4, C4a
CC       anaphylatoxin is a mediator of local inflammatory process. It induces
CC       the contraction of smooth muscle, increases vascular permeability and
CC       causes histamine release from mast cells and basophilic leukocytes.
CC   -!- SUBUNIT: Circulates in blood as a disulfide-linked trimer of alpha,
CC       beta and gamma chains. C4b interacts with CR1 (via Sushi 1 and Sushi 2
CC       domains). {ECO:0000269|PubMed:2972794, ECO:0000269|PubMed:8175757}.
CC   -!- INTERACTION:
CC       PRO_0000042699; O00187: MASP2; NbExp=4; IntAct=EBI-26369106, EBI-7965040;
CC   -!- SUBCELLULAR LOCATION: Secreted. Synapse {ECO:0000269|PubMed:26814963}.
CC       Cell projection, axon {ECO:0000269|PubMed:26814963}. Cell projection,
CC       dendrite {ECO:0000269|PubMed:26814963}.
CC   -!- TISSUE SPECIFICITY: Complement component C4 is expressed at highest
CC       levels in the liver, at moderate levels in the adrenal cortex, adrenal
CC       medulla, thyroid gland, and the kidney, and at lowest levels in the
CC       heart, ovary, small intestine, thymus, pancreas and spleen. The extra-
CC       hepatic sites of expression may be important for the local protection
CC       and inflammatory response. {ECO:0000269|PubMed:11367523}.
CC   -!- PTM: Prior to secretion, the single-chain precursor is enzymatically
CC       cleaved to yield non-identical chains alpha, beta and gamma. During
CC       activation, the alpha chain is cleaved by C1 into C4a and C4b, and C4b
CC       stays linked to the beta and gamma chains. Further degradation of C4b
CC       by C1 into the inactive fragments C4c and C4d blocks the generation of
CC       C3 convertase. The proteolytic cleavages often are incomplete so that
CC       many structural forms can be found in plasma.
CC   -!- POLYMORPHISM: The complement component C4 is the most polymorphic
CC       protein of the complement system. It is the product of 2 closely linked
CC       and highly homologous genes, C4A and C4B. Once polymorphic variation is
CC       discounted, the 2 isotypes differ by only 4 amino acids at positions
CC       1120-1125: PCPVLD for C4A and LSPVIH for C4B. The 2 isotypes bear
CC       several antigenic determinants defining Chido/Rodgers blood group
CC       system [MIM:614374]. Rodgers determinants are generally associated with
CC       C4A allotypes, and Chido with C4B. Variations at these loci involve not
CC       only nucleotide polymorphisms, but also gene number and gene size. The
CC       second copy of C4B gene present in some individuals has been called
CC       C4B_2 by the HUGO Gene Nomenclature Committee (HGNC). Some individuals
CC       may lack either C4A, or C4B gene. Partial deficiency of C4A or C4B is
CC       the most commonly inherited immune deficiency known in humans with a
CC       combined frequency over 31% in the normal Caucasian population
CC       (PubMed:11367523). Common copy-number variants of C4A and C4B affecting
CC       expression of complement component C4 in the brain have been associated
CC       with schizophrenia risk (PubMed:26814963).
CC       {ECO:0000269|PubMed:11367523, ECO:0000269|PubMed:26814963}.
CC   -!- DISEASE: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic,
CC       relapsing, inflammatory, and often febrile multisystemic disorder of
CC       connective tissue, characterized principally by involvement of the
CC       skin, joints, kidneys and serosal membranes. It is of unknown etiology,
CC       but is thought to represent a failure of the regulatory mechanisms of
CC       the autoimmune system. The disease is marked by a wide range of system
CC       dysfunctions, an elevated erythrocyte sedimentation rate, and the
CC       formation of LE cells in the blood or bone marrow.
CC       {ECO:0000269|PubMed:10092831, ECO:0000269|PubMed:17503323}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry. Interindividual copy-number variation
CC       (CNV) of complement component C4 and associated polymorphisms result in
CC       different susceptibilities to SLE. The risk of SLE susceptibility has
CC       been shown to be significantly increased among subjects with only two
CC       copies of total C4. A high copy number is a protective factor against
CC       SLE.
CC   -!- DISEASE: Complement component 4B deficiency (C4BD) [MIM:614379]: A rare
CC       defect of the complement classical pathway associated with the
CC       development of autoimmune disorders, mainly systemic lupus with or
CC       without associated glomerulonephritis. {ECO:0000269|PubMed:3265961}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA99717.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=dbRBC/BGMUT; Note=Blood group antigen gene mutation
CC       database;
CC       URL="https://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/systems_info&system=chrg";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U24578; AAA99717.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF019413; AAB67980.1; -; Genomic_DNA.
DR   EMBL; AY379860; AAR89087.1; -; Genomic_DNA.
DR   EMBL; AY379862; AAR89089.1; -; Genomic_DNA.
DR   EMBL; AY379864; AAR89091.1; -; Genomic_DNA.
DR   EMBL; AY379866; AAR89093.1; -; Genomic_DNA.
DR   EMBL; AY379868; AAR89095.1; -; Genomic_DNA.
DR   EMBL; AY379870; AAR89097.1; -; Genomic_DNA.
DR   EMBL; AY379872; AAR89099.1; -; Genomic_DNA.
DR   EMBL; AY379874; AAR89101.1; -; Genomic_DNA.
DR   EMBL; AY379876; AAR89103.1; -; Genomic_DNA.
DR   EMBL; AY379878; AAR89105.1; -; Genomic_DNA.
DR   EMBL; AY379880; AAR89107.1; -; Genomic_DNA.
DR   EMBL; AY379882; AAR89109.1; -; Genomic_DNA.
DR   EMBL; AY379884; AAR89111.1; -; Genomic_DNA.
DR   EMBL; AY379886; AAR89113.1; -; Genomic_DNA.
DR   EMBL; AY379888; AAR89115.1; -; Genomic_DNA.
DR   EMBL; AY379890; AAR89117.1; -; Genomic_DNA.
DR   EMBL; AY379892; AAR89119.1; -; Genomic_DNA.
DR   EMBL; AY379894; AAR89121.1; -; Genomic_DNA.
DR   EMBL; AY379896; AAR89123.1; -; Genomic_DNA.
DR   EMBL; AY379898; AAR89125.1; -; Genomic_DNA.
DR   EMBL; AY379900; AAR89127.1; -; Genomic_DNA.
DR   EMBL; AY379902; AAR89130.1; -; Genomic_DNA.
DR   EMBL; AY379904; AAR89132.1; -; Genomic_DNA.
DR   EMBL; AY379906; AAR89134.1; -; Genomic_DNA.
DR   EMBL; AY379908; AAR89136.1; -; Genomic_DNA.
DR   EMBL; AY379910; AAR89138.1; -; Genomic_DNA.
DR   EMBL; AY379912; AAR89139.1; -; Genomic_DNA.
DR   EMBL; AY379914; AAR89142.1; -; Genomic_DNA.
DR   EMBL; AY379916; AAR89144.1; -; Genomic_DNA.
DR   EMBL; AY379918; AAR89145.1; -; Genomic_DNA.
DR   EMBL; AY379920; AAR89148.1; -; Genomic_DNA.
DR   EMBL; AY379922; AAR89150.1; -; Genomic_DNA.
DR   EMBL; AY379924; AAR89151.1; -; Genomic_DNA.
DR   EMBL; AY379959; AAR89163.1; -; Genomic_DNA.
DR   EMBL; AY379936; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379937; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379938; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379939; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379940; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379941; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379942; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379943; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379944; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379945; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379946; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379947; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379948; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379949; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379950; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379951; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379952; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379953; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379954; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379955; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379956; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379957; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AY379958; AAR89163.1; JOINED; Genomic_DNA.
DR   EMBL; AL049547; CAB89302.1; -; Genomic_DNA.
DR   EMBL; BX679671; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; K02404; AAA59651.1; -; mRNA.
DR   EMBL; U77887; AAK49811.1; -; Genomic_DNA.
DR   EMBL; AY343497; AAQ99144.1; -; Genomic_DNA.
DR   CCDS; CCDS47405.1; -.
DR   PIR; B20807; B20807.
DR   RefSeq; NP_001002029.3; NM_001002029.3.
DR   RefSeq; NP_001229752.1; NM_001242823.2.
DR   PDB; 4XAM; X-ray; 4.20 A; A/B=20-675.
DR   PDB; 6YSQ; X-ray; 3.30 A; A/B=1-1744.
DR   PDBsum; 4XAM; -.
DR   PDBsum; 6YSQ; -.
DR   AlphaFoldDB; P0C0L5; -.
DR   SMR; P0C0L5; -.
DR   BioGRID; 107182; 7.
DR   BioGRID; 945184; 1.
DR   ComplexPortal; CPX-6156; Classical and lectin pathway C3 convertase complex C4b2a-B.
DR   DIP; DIP-47260N; -.
DR   IntAct; P0C0L5; 14.
DR   MINT; P0C0L5; -.
DR   STRING; 9606.ENSP00000415941; -.
DR   DrugBank; DB09130; Copper.
DR   DrugBank; DB00028; Human immunoglobulin G.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   DrugBank; DB14548; Zinc sulfate, unspecified form.
DR   MEROPS; I39.951; -.
DR   GlyConnect; 1146; 32 N-Linked glycans (4 sites), 1 O-Linked glycan (1 site).
DR   GlyGen; P0C0L5; 5 sites, 34 N-linked glycans (4 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; P0C0L5; -.
DR   PhosphoSitePlus; P0C0L5; -.
DR   BioMuta; C4B; -.
DR   DMDM; 476007828; -.
DR   SWISS-2DPAGE; P0C0L5; -.
DR   CPTAC; non-CPTAC-1107; -.
DR   EPD; P0C0L5; -.
DR   jPOST; P0C0L5; -.
DR   MassIVE; P0C0L5; -.
DR   PaxDb; P0C0L5; -.
DR   PeptideAtlas; P0C0L5; -.
DR   PRIDE; P0C0L5; -.
DR   ProteomicsDB; 67395; -.
DR   TopDownProteomics; P0C0L5; -.
DR   Antibodypedia; 35326; 372 antibodies from 21 providers.
DR   DNASU; 721; -.
DR   Ensembl; ENST00000375177.9; ENSP00000364321.5; ENSG00000228454.7.
DR   Ensembl; ENST00000411583.6; ENSP00000407942.2; ENSG00000228267.8.
DR   Ensembl; ENST00000435363.7; ENSP00000415941.2; ENSG00000224389.9.
DR   Ensembl; ENST00000435500.6; ENSP00000412786.2; ENSG00000233312.8.
DR   Ensembl; ENST00000449788.6; ENSP00000414200.2; ENSG00000236625.8.
DR   GeneID; 100293534; -.
DR   GeneID; 721; -.
DR   KEGG; hsa:100293534; -.
DR   KEGG; hsa:721; -.
DR   MANE-Select; ENST00000435363.7; ENSP00000415941.2; NM_001002029.4; NP_001002029.3.
DR   UCSC; uc011dpd.3; human.
DR   CTD; 100293534; -.
DR   CTD; 721; -.
DR   DisGeNET; 100293534; -.
DR   DisGeNET; 721; -.
DR   GeneCards; C4B; -.
DR   GeneCards; C4B_2; -.
DR   HGNC; HGNC:1324; C4B.
DR   HGNC; HGNC:42398; C4B_2.
DR   HPA; ENSG00000224389; Group enriched (adrenal gland, liver).
DR   MalaCards; C4B; -.
DR   MIM; 120820; gene.
DR   MIM; 152700; phenotype.
DR   MIM; 614374; phenotype.
DR   MIM; 614379; phenotype.
DR   neXtProt; NX_P0C0L5; -.
DR   OpenTargets; ENSG00000224389; -.
DR   Orphanet; 169147; Immunodeficiency due to a classical component pathway complement deficiency.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   PharmGKB; PA25904; -.
DR   VEuPathDB; HostDB:ENSG00000224389; -.
DR   eggNOG; KOG1366; Eukaryota.
DR   GeneTree; ENSGT00940000155739; -.
DR   InParanoid; P0C0L5; -.
DR   OMA; CVRQKSN; -.
DR   OrthoDB; 28894at2759; -.
DR   PhylomeDB; P0C0L5; -.
DR   TreeFam; TF313285; -.
DR   PathwayCommons; P0C0L5; -.
DR   Reactome; R-HSA-166663; Initial triggering of complement.
DR   Reactome; R-HSA-174577; Activation of C3 and C5.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   SABIO-RK; P0C0L5; -.
DR   SignaLink; P0C0L5; -.
DR   SIGNOR; P0C0L5; -.
DR   BioGRID-ORCS; 100293534; 6 hits in 65 CRISPR screens.
DR   BioGRID-ORCS; 721; 8 hits in 671 CRISPR screens.
DR   ChiTaRS; C4B; human.
DR   GeneWiki; Complement_component_4B; -.
DR   Pharos; P0C0L5; Tbio.
DR   PRO; PR:P0C0L5; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P0C0L5; protein.
DR   Bgee; ENSG00000224389; Expressed in right lobe of liver and 91 other tissues.
DR   ExpressionAtlas; P0C0L5; baseline and differential.
DR   Genevisible; P0C0L5; HS.
DR   GO; GO:0070161; C:anchoring junction; IEA:UniProtKB-KW.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0072562; C:blood microparticle; HDA:UniProtKB.
DR   GO; GO:0005601; C:classical-complement-pathway C3/C5 convertase complex; IPI:ComplexPortal.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0106139; C:symbiont cell surface; IDA:BHF-UCL.
DR   GO; GO:0045202; C:synapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0030246; F:carbohydrate binding; IDA:BHF-UCL.
DR   GO; GO:0001848; F:complement binding; IDA:BHF-UCL.
DR   GO; GO:0004866; F:endopeptidase inhibitor activity; IEA:InterPro.
DR   GO; GO:0006956; P:complement activation; IDA:ComplexPortal.
DR   GO; GO:0006958; P:complement activation, classical pathway; IEA:UniProtKB-KW.
DR   GO; GO:0032490; P:detection of molecule of bacterial origin; IDA:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0008228; P:opsonization; TAS:BHF-UCL.
DR   GO; GO:2000427; P:positive regulation of apoptotic cell clearance; IGI:BHF-UCL.
DR   GO; GO:0050778; P:positive regulation of immune response; IC:ComplexPortal.
DR   GO; GO:1903028; P:positive regulation of opsonization; IC:ComplexPortal.
DR   CDD; cd00017; ANATO; 1.
DR   Gene3D; 2.40.50.120; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 2.60.40.690; -; 1.
DR   InterPro; IPR009048; A-macroglobulin_rcpt-bd.
DR   InterPro; IPR036595; A-macroglobulin_rcpt-bd_sf.
DR   InterPro; IPR011625; A2M_N_BRD.
DR   InterPro; IPR011626; Alpha-macroglobulin_TED.
DR   InterPro; IPR000020; Anaphylatoxin/fibulin.
DR   InterPro; IPR018081; Anaphylatoxin_comp_syst.
DR   InterPro; IPR001840; Anaphylatoxn_comp_syst_dom.
DR   InterPro; IPR037569; Complement_C4A.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR001599; Macroglobln_a2.
DR   InterPro; IPR019742; MacrogloblnA2_CS.
DR   InterPro; IPR002890; MG2.
DR   InterPro; IPR041555; MG3.
DR   InterPro; IPR040839; MG4.
DR   InterPro; IPR001134; Netrin_domain.
DR   InterPro; IPR018933; Netrin_module_non-TIMP.
DR   InterPro; IPR008930; Terpenoid_cyclase/PrenylTrfase.
DR   InterPro; IPR008993; TIMP-like_OB-fold.
DR   PANTHER; PTHR11412:SF86; PTHR11412:SF86; 1.
DR   Pfam; PF00207; A2M; 1.
DR   Pfam; PF07703; A2M_BRD; 1.
DR   Pfam; PF07677; A2M_recep; 1.
DR   Pfam; PF01821; ANATO; 1.
DR   Pfam; PF01835; MG2; 1.
DR   Pfam; PF17791; MG3; 1.
DR   Pfam; PF17789; MG4; 1.
DR   Pfam; PF01759; NTR; 1.
DR   Pfam; PF07678; TED_complement; 1.
DR   PRINTS; PR00004; ANAPHYLATOXN.
DR   SMART; SM01360; A2M; 1.
DR   SMART; SM01359; A2M_N_2; 1.
DR   SMART; SM01361; A2M_recep; 1.
DR   SMART; SM00104; ANATO; 1.
DR   SMART; SM00643; C345C; 1.
DR   SUPFAM; SSF47686; SSF47686; 1.
DR   SUPFAM; SSF48239; SSF48239; 1.
DR   SUPFAM; SSF49410; SSF49410; 1.
DR   SUPFAM; SSF50242; SSF50242; 1.
DR   PROSITE; PS00477; ALPHA_2_MACROGLOBULIN; 1.
DR   PROSITE; PS01177; ANAPHYLATOXIN_1; 1.
DR   PROSITE; PS01178; ANAPHYLATOXIN_2; 1.
DR   PROSITE; PS50189; NTR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood group antigen; Cell projection;
KW   Cleavage on pair of basic residues; Complement pathway;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Immunity;
KW   Inflammatory response; Innate immunity; Phosphoprotein; Reference proteome;
KW   Secreted; Signal; Sulfation; Synapse; Systemic lupus erythematosus;
KW   Thioester bond.
FT   SIGNAL          1..19
FT   CHAIN           20..675
FT                   /note="Complement C4 beta chain"
FT                   /id="PRO_0000042699"
FT   PROPEP          676..679
FT                   /evidence="ECO:0000269|PubMed:6167582"
FT                   /id="PRO_0000042700"
FT   CHAIN           680..1446
FT                   /note="Complement C4-B alpha chain"
FT                   /id="PRO_0000042701"
FT   CHAIN           680..756
FT                   /note="C4a anaphylatoxin"
FT                   /id="PRO_0000042702"
FT   CHAIN           757..1446
FT                   /note="C4b-B"
FT                   /id="PRO_0000042703"
FT   CHAIN           957..1336
FT                   /note="C4d-B"
FT                   /id="PRO_0000042704"
FT   PROPEP          1447..1453
FT                   /id="PRO_0000042705"
FT   CHAIN           1454..1744
FT                   /note="Complement C4 gamma chain"
FT                   /id="PRO_0000042706"
FT   DOMAIN          702..736
FT                   /note="Anaphylatoxin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00022"
FT   DOMAIN          1595..1742
FT                   /note="NTR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00295"
FT   MOD_RES         918
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P0C0L4"
FT   MOD_RES         1417
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:3944109"
FT   MOD_RES         1420
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:3944109"
FT   MOD_RES         1422
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:3944109"
FT   CARBOHYD        226
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12754519"
FT   CARBOHYD        862
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1328
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:16740002"
FT   CARBOHYD        1391
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:14760718"
FT   DISULFID        702..728
FT                   /evidence="ECO:0000250"
FT   DISULFID        703..735
FT                   /evidence="ECO:0000250"
FT   DISULFID        716..736
FT                   /evidence="ECO:0000250"
FT   DISULFID        1595..1673
FT                   /evidence="ECO:0000250"
FT   DISULFID        1618..1742
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        1010..1013
FT                   /note="Isoglutamyl cysteine thioester (Cys-Gln)"
FT   VARIANT         347
FT                   /note="S -> Y (in allotype C4B-long; dbSNP:rs139889867)"
FT                   /evidence="ECO:0000269|PubMed:14574404, ECO:0000269|Ref.2"
FT                   /id="VAR_023729"
FT   VARIANT         478
FT                   /note="P -> L (in allotype C4B1-hi)"
FT                   /id="VAR_069160"
FT   VARIANT         907
FT                   /note="T -> A (in allotype C4B-long and allotype C4B2;
FT                   dbSNP:rs796750528)"
FT                   /evidence="ECO:0000269|PubMed:14574404, ECO:0000269|Ref.2,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_023730"
FT   VARIANT         1073
FT                   /note="G -> D (in allotype C4B2 and allotype C4B5-Rg1;
FT                   dbSNP:rs2258218)"
FT                   /evidence="ECO:0000269|PubMed:6546707, ECO:0000269|Ref.3"
FT                   /id="VAR_023731"
FT   VARIANT         1176
FT                   /note="S -> N (in allotype C4B1a; dbSNP:rs2746414)"
FT                   /evidence="ECO:0000269|PubMed:14989716"
FT                   /id="VAR_023732"
FT   VARIANT         1207
FT                   /note="A -> V (in allotype C4B5-Rg1; dbSNP:rs2229403)"
FT                   /evidence="ECO:0000269|PubMed:14989716"
FT                   /id="VAR_023734"
FT   VARIANT         1210
FT                   /note="R -> L (in allotype C4B5-Rg1; dbSNP:rs2229409)"
FT                   /evidence="ECO:0000269|PubMed:14989716"
FT                   /id="VAR_023735"
FT   VARIANT         1317
FT                   /note="I -> F (in allotype C4B1-SC01; dbSNP:rs2023616)"
FT                   /evidence="ECO:0000269|PubMed:8575831"
FT                   /id="VAR_069161"
FT   MUTAGEN         1120
FT                   /note="L->P: No effect on hemolytic activity, nor on
FT                   C1-dependent binding to IgG."
FT                   /evidence="ECO:0000269|PubMed:2395880"
FT   MUTAGEN         1121
FT                   /note="S->C: 30-40% decrease in hemolytic activity and
FT                   C1-dependent binding to IgG."
FT                   /evidence="ECO:0000269|PubMed:2395880"
FT   MUTAGEN         1124
FT                   /note="I->A: 50-60% decrease in hemolytic activity and
FT                   C1-dependent binding to IgG."
FT                   /evidence="ECO:0000269|PubMed:2395880"
FT   MUTAGEN         1125
FT                   /note="H->A: 20% decrease in hemolytic activity, 2-fold
FT                   increase in C1-dependent binding to IgG."
FT                   /evidence="ECO:0000269|PubMed:2395880"
FT   MUTAGEN         1125
FT                   /note="H->D: 2.5-3 fold-decrease in hemolytic activity,
FT                   3-fold increase in C1-dependent binding to IgG."
FT                   /evidence="ECO:0000269|PubMed:2395880"
FT   CONFLICT        714
FT                   /note="R -> S (in Ref. 3; AAR89101)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        729
FT                   /note="R -> Q (in Ref. 3; AAR89127)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        980..981
FT                   /note="VT -> LQ (in Ref. 1; AAA99717)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1013
FT                   /note="Q -> E (in Ref. 8; AA sequence, 9; AA sequence and
FT                   10; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1109..1110
FT                   /note="SQ -> IA (in Ref. 9; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1271
FT                   /note="H -> V (in Ref. 9; AA sequence and 13; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1300
FT                   /note="R -> V (in Ref. 9; AA sequence and 13; AA sequence)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1654
FT                   /note="T -> RA (in Ref. 1; AAA99717)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1698
FT                   /note="H -> Q (in Ref. 1; AAA99717)"
FT                   /evidence="ECO:0000305"
FT   STRAND          22..32
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          37..45
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          52..60
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          66..69
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          72..76
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          78..80
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          82..87
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           91..97
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          107..113
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   TURN            115..120
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          126..135
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          139..146
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          148..150
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          155..163
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          167..169
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          174..179
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          181..183
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          185..191
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          194..203
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          210..221
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          228..233
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          240..250
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          252..254
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          262..270
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          278..287
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          293..295
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          301..304
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          309..314
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           316..325
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           330..332
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          337..346
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   TURN            347..349
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          352..357
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          361..364
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          366..370
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          384..392
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          402..409
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          412..414
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          417..424
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          430..435
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          443..450
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          452..454
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          456..463
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          472..476
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          488..498
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          504..511
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          514..522
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          525..532
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           535..537
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          539..549
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          552..561
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          571..574
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          586..605
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           608..611
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           622..628
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           629..631
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          641..643
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           644..650
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          652..655
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1465..1474
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1484..1489
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1494..1496
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           1498..1501
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           1502..1504
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1506..1509
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1512..1517
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1519..1527
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1534..1536
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1539..1544
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1554..1560
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1564..1567
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1573..1575
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1581..1584
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1587..1590
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           1613..1618
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1625..1634
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1640..1652
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1664..1670
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1681..1687
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1695..1699
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   STRAND          1708..1711
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           1715..1718
FT                   /evidence="ECO:0007829|PDB:6YSQ"
FT   HELIX           1724..1739
FT                   /evidence="ECO:0007829|PDB:6YSQ"
SQ   SEQUENCE   1744 AA;  192751 MW;  E724B85F7FA673C5 CRC64;
     MRLLWGLIWA SSFFTLSLQK PRLLLFSPSV VHLGVPLSVG VQLQDVPRGQ VVKGSVFLRN
     PSRNNVPCSP KVDFTLSSER DFALLSLQVP LKDAKSCGLH QLLRGPEVQL VAHSPWLKDS
     LSRTTNIQGI NLLFSSRRGH LFLQTDQPIY NPGQRVRYRV FALDQKMRPS TDTITVMVEN
     SHGLRVRKKE VYMPSSIFQD DFVIPDISEP GTWKISARFS DGLESNSSTQ FEVKKYVLPN
     FEVKITPGKP YILTVPGHLD EMQLDIQARY IYGKPVQGVA YVRFGLLDED GKKTFFRGLE
     SQTKLVNGQS HISLSKAEFQ DALEKLNMGI TDLQGLRLYV AAAIIESPGG EMEEAELTSW
     YFVSSPFSLD LSKTKRHLVP GAPFLLQALV REMSGSPASG IPVKVSATVS SPGSVPEVQD
     IQQNTDGSGQ VSIPIIIPQT ISELQLSVSA GSPHPAIARL TVAAPPSGGP GFLSIERPDS
     RPPRVGDTLN LNLRAVGSGA TFSHYYYMIL SRGQIVFMNR EPKRTLTSVS VFVDHHLAPS
     FYFVAFYYHG DHPVANSLRV DVQAGACEGK LELSVDGAKQ YRNGESVKLH LETDSLALVA
     LGALDTALYA AGSKSHKPLN MGKVFEAMNS YDLGCGPGGG DSALQVFQAA GLAFSDGDQW
     TLSRKRLSCP KEKTTRKKRN VNFQKAINEK LGQYASPTAK RCCQDGVTRL PMMRSCEQRA
     ARVQQPDCRE PFLSCCQFAE SLRKKSRDKG QAGLQRALEI LQEEDLIDED DIPVRSFFPE
     NWLWRVETVD RFQILTLWLP DSLTTWEIHG LSLSKTKGLC VATPVQLRVF REFHLHLRLP
     MSVRRFEQLE LRPVLYNYLD KNLTVSVHVS PVEGLCLAGG GGLAQQVLVP AGSARPVAFS
     VVPTAATAVS LKVVARGSFE FPVGDAVSKV LQIEKEGAIH REELVYELNP LDHRGRTLEI
     PGNSDPNMIP DGDFNSYVRV TASDPLDTLG SEGALSPGGV ASLLRLPRGC GEQTMIYLAP
     TLAASRYLDK TEQWSTLPPE TKDHAVDLIQ KGYMRIQQFR KADGSYAAWL SRGSSTWLTA
     FVLKVLSLAQ EQVGGSPEKL QETSNWLLSQ QQADGSFQDL SPVIHRSMQG GLVGNDETVA
     LTAFVTIALH HGLAVFQDEG AEPLKQRVEA SISKASSFLG EKASAGLLGA HAAAITAYAL
     TLTKAPADLR GVAHNNLMAM AQETGDNLYW GSVTGSQSNA VSPTPAPRNP SDPMPQAPAL
     WIETTAYALL HLLLHEGKAE MADQAAAWLT RQGSFQGGFR STQDTVIALD ALSAYWIASH
     TTEERGLNVT LSSTGRNGFK SHALQLNNRQ IRGLEEELQF SLGSKINVKV GGNSKGTLKV
     LRTYNVLDMK NTTCQDLQIE VTVKGHVEYT MEANEDYEDY EYDELPAKDD PDAPLQPVTP
     LQLFEGRRNR RRREAPKVVE EQESRVHYTV CIWRNGKVGL SGMAIADVTL LSGFHALRAD
     LEKLTSLSDR YVSHFETEGP HVLLYFDSVP TSRECVGFEA VQEVPVGLVQ PASATLYDYY
     NPERRCSVFY GAPSKSRLLA TLCSAEVCQC AEGKCPRQRR ALERGLQDED GYRMKFACYY
     PRVEYGFQVK VLREDSRAAF RLFETKITQV LHFTKDVKAA ANQMRNFLVR ASCRLRLEPG
     KEYLIMGLDG ATYDLEGHPQ YLLDSNSWIE EMPSERLCRS TRQRAACAQL NDFLQEYGTQ
     GCQV
//
